Drug intelligence / Profile preview

KIN-004

Development stage: Preclinical
Lead developer: XOMA
Modality: Small Molecules
Administration: Intravenous

Overview

**KIN-004** is a small molecule inhibitor of cyclin-dependent kinase 12 (CDK12) developed by Kinnate Biopharma, Inc. CDK12 is a kinase involved in regulating transcription by phosphorylating RNA polymerase II, and its inhibition disrupts DNA damage repair pathways, making it a promising target for oncology. The drug is being explored for solid tumors, particularly those with CDK12 alterations, such as ovarian cancer, triple-negative breast cancer, and metastatic castration-resistant prostate cancer, as part of Kinnate's precision medicine approach targeting genetically defined cancers.

Targets

CDK12

Beyond the preview

Go deeper on KIN-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIN-004.

Explore the full profile